Delcath inks supply deal with Tillomed Laboratories in Europe

Delcath Systems (NSDQ:DCTH) said today that it inked a commercial supply deal with Tillomed Laboratories in Europe.

According to the deal, Tillomed Labs is slated to provide Delcath with melphalan – the drug used in Delcath’s hepatic Chemosat delivery system. In Europe, the drug-device combo is approved to treat liver cancer.

Get the full story at our sister site, Drug Delivery Business News.

The post Delcath inks supply deal with Tillomed Laboratories in Europe appeared first on MassDevice.

from MassDevice http://ift.tt/2FjiFob